Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LY96 | Q9Y6Y9 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335548 | 1.00 | MAPT (0.48) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL2335538 | 1.00 | MAPT (0.48) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL17453047 | 1.00 | MAPT (0.48) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL17453046 | 1.00 | MAPT (0.48) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL2339111 | 1.00 | MAPT (0.48) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL2336925 | 0.93 | MAPT (0.46) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL2336920 | 0.93 | MAPT (0.46) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL2335003 | 0.88 | LMNA (0.44) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL2335000 | 0.88 | LMNA (0.44) | MAPTLMNAKMT2AMAPK1POLB | |
| SCHEMBL3336078 | 0.88 | LMNA (0.54) | MAPTLMNAKMT2APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016985-A1 | SHORT-CHAIN FATTY ACID HEXOSAMINE ANALOGS AND THEIR USE IN TISSUE ENGINEERING APPLICATIONS | THE JOHNS HOPKINS UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-20160016985-A1 | SHORT-CHAIN FATTY ACID HEXOSAMINE ANALOGS AND THEIR USE IN TISSUE ENGINEERING APPLICATIONS | THE JOHNS HOPKINS UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016985-A1 | SHORT-CHAIN FATTY ACID HEXOSAMINE ANALOGS AND THEIR USE IN TISSUE ENGINEERING APPLICATIONS | NFKBIA, IKBKG, NFKB1 | MAPT 4525/4885LMNA 750/4885KMT2A 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.